08:00 , Jan 14, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Leishmania glycosomal phosphoenolpyruvate carboxykinase (PEPCK)

Infectious disease INDICATION: Leishmaniasis Mouse and patient sample studies suggest a PEPCK-based vaccine could help treat leishmaniasis. Analysis of parasitic peptides presented by dendritic cells from mice infected with Leishmania major identified a PEPCK peptide, conserved across...
08:00 , Jan 22, 2007 |  BioCentury  |  Tools & Techniques

DHEA derivative as insulin booster

Treatments for Type II diabetes typically take one of three therapeutic routes: increase insulin production, reduce glucose production or sensitize the effects of insulin. Hollis-Eden Pharmaceuticals Inc. believes that its HE3286 - a novel compound...
08:00 , Mar 3, 2003 |  BC Week In Review  |  Company News

Human Genome Sciences other research news

Researchers published in Nature Biotechnology the identification of BMP-9 using high throughput cell-based assays. In culture, BMP-9 reduced phosphoenolpyruvate carboxykinase (PEPCK) expression in hepatocytes and activated Akt kinase in differentiated myotubes. Both kinases are involved...
08:00 , Feb 2, 1998 |  BC Week In Review  |  Company News

OSI, Wyeth-Ayerst deal

Wyeth-Ayerst exercised its option under a 1992 research agreement with OSIP for an exclusive worldwide license to develop small molecule, gene transcription-based compounds that modulate the expression of phosphoenol pyruvate carboxy kinase (PEPCK) to treat...